[Multi-Modal Serial Therapy for Primary Liver Cancer in Senile Patients: a Report of 153 Cases].

Li Zhou,Jing-an Rui,Shao-bin Wang,Shu-guang Chen,Qiang Qu,Xue Wei,Kai Han,Ning Zhang,Hai-tao Zhao

DOI: https://doi.org/10.3760/j.issn:0253-3766.2003.04.027

2003-01-01

Abstract:OBJECTIVETo study the feasibility and validity of multi-modal serial therapy for primary liver cancer in senile patients.METHODS153 senile primary liver cancer patients (>or= 60 years) were given multi-modal serial therapy from June 1993 to December 2000. Hepatectomy was performed in 37, deep cryosurgery in 32 and non-operative therapy in 84 (intervention as chief therapy in 81, combined local and intervention therapy in 3). The multi-course intervention therapy was given postoperatively in hepatectomy and cryosurgery groups, while bioimmunotherapy and traditional Chinese medicine were used in all groups.RESULTSThe 1-, 3- and 5-year survival rates in the hepatectomy group were 78.4%, 46.4% and 35.7%, without operative mortality. The 1- and 3- and 5-year year survival rates in the cryosurgery group were 64.5%, 40.9% and 25.0% with mortality of 3.1%. Among patients with non-operative therapy, the 1- and 3- and 5-year year survival rates in intervention group were 47.5%, 23.5% and 4.3%. The operative mortality was 1.2%. The 3 patients who received combined local and intervention therapy have survived for 2.5, 3.8 and 7.1 years.CONCLUSIONMulti-modal serial therapy with surgical treatment as the chief means, being precise in the effect and good in safety, is feasible and valid for primary liver cancer in senile patients.